Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
about
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsA Review of Management of Inflammation in the HIV PopulationDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyPharmGKB summary: abacavir pathwayRisks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir.Inflammation, Immune Activation, and Antiretroviral Therapy in HIVEvaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV diseaseEffects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosisPharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted studyRisk of cardiovascular disease from antiretroviral therapy for HIV: a systematic reviewNo risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Epidemiology and management of antiretroviral-associated cardiovascular disease.Relaxation effect of abacavir on rat basilar arteries.Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label studyAbacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclaseIs there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort studyShort communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimensInflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population.Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection.Myocardial infarction caused by pharmacological substances - case description and literature reviewAgeing with HIV: a multidisciplinary review.Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?Epidemiology of ischemic heart disease in HIV.Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score.Abacavir + dolutegravir + lamivudine for the treatment of HIV.The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol.Moving forward with treatment options for HIV-infected children.Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population.Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking.Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
P2860
Q27024262-43281B14-783F-455F-8AA4-F4BF2A2BAC41Q28078962-85BC041F-DFCF-47D3-B54C-974A9C37DB84Q28543075-3E9D164C-87CF-4F79-AA77-26DF2772BCCFQ33819062-23B914CC-1F81-4622-B702-2B0E7A676DC3Q33841718-B8468BF7-2BCD-453C-A547-B35A6F6A8BECQ33863327-3A2731AB-D74F-4EB7-9A92-B5E5E919CA7AQ33912595-661CD09F-1840-474F-887D-02F10E7AA237Q34039680-ACBE6DCE-8231-4D8E-BA1D-07BD3B980285Q34077477-709543F8-8165-4E2D-A62F-51EECDC33C8AQ34157856-BADF1BD3-A03C-4410-9B2D-16F9A8377655Q34430776-56B8DF9F-5960-4FCB-8177-1309B3777847Q34477917-6B670910-9B1C-4173-BA40-9C9A8151582BQ34651525-D7A057C7-2537-4C3F-9A8C-A447E1DFD6ECQ34708243-8344B1B2-E8CA-47B6-9BB0-A3A7039ED72CQ34736194-C7528A0B-70A8-4E48-96E7-2050AFB25778Q35233168-E3881558-CC74-4B19-AEE8-6632E0D5A367Q35338096-3D225A05-BEE9-4FDD-8D96-FEA06FF36BAEQ35597616-70E0EA5D-905B-4887-9685-A958AE17F0AEQ35623357-8AE56E85-5D0B-4DBB-BF5A-0BC4C9EE5F9DQ35737682-3E19F569-F918-4BFE-9D7D-E5CDBC7C0597Q35977313-530729D0-D518-43EB-82EC-EED54AEFA1D6Q36098224-978CE810-A4A8-4CDC-AC0C-E6E455EF7F0EQ36419549-8FEF66FA-55FF-4972-8A37-BD2551323296Q36578046-17C8D0A6-8094-4F2F-952E-E295E4CF7D73Q36693929-1AADFCF6-8728-4602-9510-BB2D14BE0B7FQ37665526-7699EB8D-0C31-4FB0-9102-1F5892DC4312Q37993138-D751B8DE-BE13-4EA3-ADFE-AF1FB23DD1EDQ38172305-C8C35E79-A679-4B9F-858C-79F9E4BBE94BQ38191218-C1634C7E-179A-4314-AA7B-4CBD915A5017Q38490362-058C40C8-1CAE-4A42-84AC-C9F47E60031EQ38596011-86C98590-3DA3-467E-82F5-1D4EFD06F899Q38629009-93CE0696-9AD0-4A60-942F-05621E9E9FB2Q38950123-8C13176C-320B-4C7A-B76B-ED82BE03D9AFQ38951349-8AA687F8-8708-4F65-9DFE-2EA1250A82B2Q40047379-175B96D3-D442-4254-A2C3-19ACE613F57BQ40063042-0061DCBC-1BCA-4282-8123-81181625AE90Q40070894-B7933B87-EABC-445E-B599-4BBCF3B7FC59Q41540052-5AADC50A-5428-482E-9464-8ACBE800E8C5Q42609996-4827BC83-E057-4841-AA8C-59572623D14DQ48856213-F9DD0059-FDFD-4754-B0DB-9115A1D26CCE
P2860
Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Abacavir and risk of myocardia ...... based nationwide cohort study.
@en
Abacavir and risk of myocardia ...... based nationwide cohort study.
@nl
type
label
Abacavir and risk of myocardia ...... based nationwide cohort study.
@en
Abacavir and risk of myocardia ...... based nationwide cohort study.
@nl
prefLabel
Abacavir and risk of myocardia ...... based nationwide cohort study.
@en
Abacavir and risk of myocardia ...... based nationwide cohort study.
@nl
P2093
P1433
P1476
Abacavir and risk of myocardia ...... based nationwide cohort study.
@en
P2093
C Pedersen
C S Larsen
D K Farkas
G Kronborg
G Pedersen
H T Sørensen
J Gerstoft
P304
P356
10.1111/J.1468-1293.2009.00751.X
P50
P577
2009-08-13T00:00:00Z